|
Changes to This Summary (08/28/2009)
The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available. This section describes the latest
changes made to this summary as of the date above.
Cellular Classification of Adult Non-Hodgkin Lymphoma 1
Added text 2 to state that prognostic factors associated with symptoms requiring therapy include age 70 or older, beta-2-microglobulin of 3 mg/dL or more, and increased serum lactate dehydrogenase (cited Dhodapkar et al. as reference 36).
Added Treon et al. as reference 39 2.
Added Martin et al. as reference 49 3.
Revised text 3 to state that alkylating agents or purine nucleoside analogs can predispose patients to myelodysplasia or acute leukemia (cited Leleu et al. as reference 50).
Added Fu et al. as reference 109 4.
Added Le Gouill et al. as reference 144 5.
Added Shimada et al. as reference 175 6.
Added Herrmann et al. as reference 209 7.
Added Geisler et al. as reference 226 7.
Treatment Option Overview 8
Revised text 9 to state that for as many as 3 decades after diagnosis, patients are at a significantly elevated risk for second primary cancers (cited Hemminki et al. as reference 5).
Added Senff et al. as reference 51 10.
Aggressive, Stage I and Contiguous Stage II Adult Non-Hodgkin Lymphoma 11
Added Persky et al. as reference 6 12 and level of evidence 3iiiDiii.
Added text 12 to state that a preliminary study using CHOP with or without etoposide for patients older than 60 years suggested improvement in EFS and OS for treatment delivered every 2 weeks versus the standard 3-week regimen (cited 2004 Pfreundschuh et al. as reference 7).
Added text 13 on the RICOVER-60 study (cited 2008 Pfreundschuh et al. as reference 8 and level of evidence 1iiA).
Indolent, Noncontiguous Stage II/III/IV Adult Non-Hodgkin Lymphoma 14
Added Marcus et al. as reference 21 15.
Added bendamustine 16 as a standard treatment option/oral alkylating agent (with or without steroids) (cited Robinson et al. as reference 44).
Added Morschhauser et al. as reference 53 17.
Added Gyan et al. as reference 64 17.
Aggressive, Noncontiguous Stage II/III/IV Adult Non-Hodgkin Lymphoma 18
Added text 19 to state that a preliminary study using CHOP with or without etoposide for patients older than 60 years suggested improvement in EFS and OS for treatment delivered every 2 weeks versus the standard 3-week regimen (cited 2004 Pfreundschuh et al. as reference 12).
Added text 19 on the RICOVER-60 study (cited 2008 Pfreundschuh et al. as reference 13 and level of evidence 1iiA).
Indolent, Recurrent Adult Non-Hodgkin Lymphoma 20
Added Khouri et al. as reference 25 21 and Sebban et al. as reference 26.
Aggressive, Recurrent Adult Non-Hodgkin Lymphoma 22
Added Vellenga et al. as reference 8 23.
Added Rezvani et al. as reference 15 23. |
